Pharmacokinetic and pharmacodynamic properties of oral voriconazole in patients with invasive fungal infections

Pharmacotherapy

Volumn 35, Issue 9, 2015, Pages 797-804

  Wang, Taotao ^a   Xie, Jiao ^a   Wang, Yan ^a   Zheng, Xiaowei ^a   Lei, Jin'E ^a   Wang, Xue ^a   Dong, Haiyan ^a   Yang, Qianting ^a   Chen, Limei ^a   Xing, Jianfeng ^b   Dong, Yalin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

fAUC24:MIC; fCmin:MIC; invasive fungal infections; noncompartmental analysis; pharmacodynamics; pharmacokinetics; voriconazole

Indexed keywords

CYTOCHROME P450 2C19; DEXAMETHASONE; OMEPRAZOLE; SULFAMETHOXAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYP2C19 GENE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESPONSE; FEMALE; HOSPITAL PATIENT; HUMAN; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PHARMACODYNAMICS; PICHIA KUDRIAVZEVII; PROSPECTIVE STUDY; PULMONARY CANDIDIASIS; SINGLE NUCLEOTIDE POLYMORPHISM; STEADY STATE; SYSTEMIC MYCOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; BIOLOGICAL MODEL; HOSPITALIZATION; MICROBIAL SENSITIVITY TEST; MYCOSES; ORAL DRUG ADMINISTRATION; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; AREA UNDER CURVE; FEMALE; HOSPITALIZATION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; MYCOSES; PROSPECTIVE STUDIES; VORICONAZOLE; YOUNG ADULT;

EID: 84942522600     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1631     Document Type: Article

References (35)

1. Pfaller MA, Pappas PG, Wingard JR,. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006; 43 (Suppl 1): S3-14.
2. Bitar D, Lortholary O, Le Strat Y, et al., Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis 2014; 7: 1163-9.
3. Demitrovicova A, Liskova A, Valach M, et al., Fungal neuroinfections and fungaemia: unexpected increase of mortality from invasive fungal infections in 2005-2011 in comparison to 1989-1998: analysis of 210 cases. Neuro Endocrinol Lett 2013; 34 (Suppl 1): 32-5.
4. Nailor MD, Chandrasekar PH,. Antifungal drugs: predicting clinical efficacy with pharmacodynamics. Expert Rev Clin Pharmacol 2009; 4: 373-9.
5. Cocchi S, Codeluppi M, Venturelli C, et al., Fusarium verticillioides fungemia in a liver transplantation patient: successful treatment with voriconazole. Diagn Microbiol Infect Dis 2011; 4: 438-41.
6. Theuretzbacher U, Ihle F, Derendorf H,. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 7: 649-63.
7. Hyland R, Jones BC, Smith DA,. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 5: 540-7.
8. Weiss J, Ten Hoevel MM, Burhenne J, et al., CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 2009; 2: 196-204.
9. Ikeda Y, Umemura K, Kondo K, et al., Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 6: 587-8.
10. Wang T, Chen S, Sun J, et al., Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections. J Antimicrob Chemother 2014; 2: 463-70.
11. Andes D, Marchillo K, Stamstad T, Conklin R,. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 10: 3165-9.
12. Troke PF, Hockey HP, Hope WW,. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011; 10: 4782-8.
13. De Pauw B, Walsh TJ, Donnelly JP, et al., Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 12: 1813-21.
14. Marr KA, Balajee SA, McLaughlin L, et al., Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 3: 641-9.
15. Persat F, Ranque S, Derouin F, et al., Contribution of the (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008; 3: 1009-13.
16. Gabriel S, Ziaugra L, Tabbaa D,. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet 2009; 2: 2-12.
17. Institute CaLS. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
18. Institute CaLS. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard M27-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2002.
19. Pascual A, Calandra T, Bolay S, et al., Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 2: 201-11.
20. Segal BH, Herbrecht R, Stevens DA, et al., Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008; 5: 674-83.
21. Ashbee HR, Barnes RA, Johnson EM, et al., Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother 2014; 5: 1162-76.
22. Lipp HP,. Antifungal agents-clinical pharmacokinetics and drug interactions. Mycoses 2008; 51 (Suppl 1): 7-18.
23. Leveque D, Nivoix Y, Jehl F, Herbrecht R,. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006; 4: 274-84.
24. Trifilio S, Pennick G, Pi J, et al., Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 8: 1532-5.
25. Pascual A, Nieth V, Calandra T, et al., Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007; 1: 137-43.
26. Scott LJ, Simpson D,. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 2007; 2: 269-98.
27. Pascual A, Csajka C, Buclin T, et al., Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012; 3: 381-90.
28. Park WB, Kim NH, Kim KH, et al., The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Clin Infect Dis 2012; 8: 1080-7.
29. Pai MP, Lodise TP,. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother 2011; 6: 2601-5.
30. Pfaller MA, Diekema DJ, Rex JH, et al., Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 3: 819-26.
31. Schwartz S, Ruhnke M, Ribaud P, et al., Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005; 8: 2641-5.
32. Almyroudis NG, Kontoyiannis DP, Sepkowitz KA, et al., Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis 2006; 11: 1449-55.
33. Matsumoto K, Ikawa K, Abematsu K, et al., Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009; 1: 91-4.
34. Ueda K, Nannya Y, Kumano K, et al., Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009; 5: 592-9.
35. Johnson HJ, Han K, Capitano B, et al., Voriconazole pharmacokinetics in liver transplant recipients. Antimicrob Agents Chemother 2010; 2: 852-9.